russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2017-2-119-124russjcardiol-1287Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWАНТИИШЕМИЧЕСКИЙ МЕТАБОЛИЧЕСКИЙ МОДУЛЯТОР ТРИМЕТАЗИДИН В ЛЕЧЕНИИ ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦАANTIISCHEMIC METABOLIC MODULATOR TRIMETAZIDINE IN TREATMENT OF CORONARY HEART DISEASEЛупановВ. П.LupanovV. P.

отдел проблем атеросклероза НИИ кардиологии им. А.Л. Мясникова

д.м.н., профессор, в.н.с. 

Lupanovvp@mail.ruФГБУ Российский кардиологический научно-производственный комплекс Минздрава России, МоскваРоссияRussian Cardiological Research-and-Production Complex of the Ministry of Health, MoscowRussian Federation20172702201702119124Copyright © Лупанов В.П., 20172017Лупанов В.П.Lupanov V.P.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/1287

Данные мета-анализа показывают, что добавление к стандартной терапии триметазидина (ТМЗ) значительно увеличивает толерантность к нагрузке у больных с ишемической болезнью сердца (ИБС). У пациентов с хронической сердечной недостаточностью, обусловленной ИБС, также улучшается состояние при приеме ТМЗ. Отсутствуют четкие доказательства, что ТМЗ особенно эффективен у больных ИБС при сопутствующем сахарном диабете. ТМЗ обладает выраженным антиангинальным эффектом в комбинации с другими лекарственными средствами, что, несомненно, улучшает качество жизни пациентов.

Meta-analytic data shows that addition of trimetazidine (TMZ) to standard therapy increases significantly exercise tolerance in ischemic heart disease (IHD) patients. In heart failure due to IHD, condition improves as well, administering TMZ. There is no strict evidence that TMZ is especially effective in people with comorbid diabetes. TMZ shows significant antianginal effect in combination with other medications that is, certainly, improves life quality of patients.

хроническая ишемическая болезнь сердцаантиангинальная терапиятриметазидинтолерантность к нагрузкехроническая сердечная недостаточностьчрескожные коронарные вмешательствамета-анализchronic ischemic heart diseaseantianginal therapytrimetazidineexercise tolerancechronic heart failurepercutaneous coronary interventionsmeta-analysisReferences2013 ESC guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology (Montalescot G, Sechtem U, Achenbach S., et al.) Eur Heart J 2013; 34: 2949- 3003.2013 ESC guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology (Montalescot G, Sechtem U, Achenbach S., et al.) Eur Heart J 2013; 34: 2949- 3003.Ohman EM, Alexander KP. The challenges with chronic angina. N Engl J Med 2014; 71: 1152-3.Ohman EM, Alexander KP. The challenges with chronic angina. N Engl J Med 2014; 71: 1152-3.Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease. Circulation 2014; 130: 1749-67.Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease. Circulation 2014; 130: 1749-67.Marzilli M. Cardioprotective effects of trimetazidine: a review. Curr Med Res Opin 2003: 19: 661-72.Marzilli M. Cardioprotective effects of trimetazidine: a review. Curr Med Res Opin 2003: 19: 661-72.Lupanov VP. Medicines affecting the metabolism of the myocardium. In the book. Rational pharmacotherapy of cardiovascular diseases. Ed. Chazov EI, Karpov YuA. M., Litterra, 2015: 298-300. Russian (Лупанов В. П. Лекарственные средства, влияющие на метаболизм миокарда. В кн. Рациональная фармакотерапия сердечно-сосуди- стых заболеваний. Под.ред. Е.И. Чазова, Ю.А. Карпова, 2 изд., М., Литтерра 2015: 298-300).Lupanov VP. Medicines affecting the metabolism of the myocardium. In the book. Rational pharmacotherapy of cardiovascular diseases. Ed. Chazov EI, Karpov YuA. M., Litterra, 2015: 298-300. Russian (Лупанов В. П. Лекарственные средства, влияющие на метаболизм миокарда. В кн. Рациональная фармакотерапия сердечно-сосуди- стых заболеваний. Под.ред. Е.И. Чазова, Ю.А. Карпова, 2 изд., М., Литтерра 2015: 298-300).Сesar LA, Gowdak LH, Mansur AP. The metabolic treatment of patients with coronary artery disease: effects on quality of life and effort angina. Curr Pharm Des 2009; 15(8): 841-9. 7. Peng S, Zhao M, Wan J, et al. The efficacy of trimetazidine on stable angina pectoris: a meta-analysis of randomized clinical trials. Int J Cardiol 2014; 177: 780-5.Сesar LA, Gowdak LH, Mansur AP. The metabolic treatment of patients with coronary artery disease: effects on quality of life and effort angina. Curr Pharm Des 2009; 15(8): 841-9. 7. Peng S, Zhao M, Wan J, et al. The efficacy of trimetazidine on stable angina pectoris: a meta-analysis of randomized clinical trials. Int J Cardiol 2014; 177: 780-5.Zhang L, Lu Y, Jiang H, et al. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol 2012; 59(10): 913-20.Zhang L, Lu Y, Jiang H, et al. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol 2012; 59(10): 913-20.Guarini G, Huqi A, Morrone D, et al. Pharmacological agents targeting myocardial metabolism for the management of chronic stable angina: an update. Cardiovasc Drugs Ther 2016; 30(4): 379-1.Guarini G, Huqi A, Morrone D, et al. Pharmacological agents targeting myocardial metabolism for the management of chronic stable angina: an update. Cardiovasc Drugs Ther 2016; 30(4): 379-1.Paranq P, Singh B, Arora R. Metabolic modulators for chronic cardiac ischemia. J Cardiovasc Pharmacol Ther 2005: dec, 10(4); 217-23.Paranq P, Singh B, Arora R. Metabolic modulators for chronic cardiac ischemia. J Cardiovasc Pharmacol Ther 2005: dec, 10(4); 217-23.Teng Y. Effect of trimetazidine in the treatment of stable angina pectoris. Clin J Mod Drug Appl 2011; 11: 187-8.Teng Y. Effect of trimetazidine in the treatment of stable angina pectoris. Clin J Mod Drug Appl 2011; 11: 187-8.Bucci M, Borra R, Nagren K, et al. Trimetazidine reduces endogenous free fatty acid oxidation and improves myocardial efficiency in obese humans. Cardiovasc Ther 2012; 30: 333-41.Bucci M, Borra R, Nagren K, et al. Trimetazidine reduces endogenous free fatty acid oxidation and improves myocardial efficiency in obese humans. Cardiovasc Ther 2012; 30: 333-41.Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxydation to glucose oxidation by inhibiting mitochondrial longchain 3-retoacyl coenzyme a thiolase. Circ Res 2000; 86(5): 580-8.Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxydation to glucose oxidation by inhibiting mitochondrial longchain 3-retoacyl coenzyme a thiolase. Circ Res 2000; 86(5): 580-8.Dezsi CA. Trimetazidine in practice review of the clinical and experimental evidence. Am J Ther 2016; 23(3): e871-e9.Dezsi CA. Trimetazidine in practice review of the clinical and experimental evidence. Am J Ther 2016; 23(3): e871-e9.Oganov RG, Glezer MG, Deev AD. Results of the Russian study PARALLEL. The program identifies patients with ineffective therapy with beta-blockers and evaluating the effectiveness of adding the therapy of Trimetazidine MV or isosorbide dinitrate in stable angina. Kardiologija 2007; 3: 4-13. Russian (Оганов Р. Г., Глезер М. Г., Деев Ф. В. Результаты Российского исследования ПАРАЛЛЕЛЬ. Программа по выявлению пациентов с неэффективной терапией бета-адреноблокаторами и сравнительной оценке эффективности добавления к терапии триметазидина МВ или изосорбида динитрата при стабильной стенокардии. Кардиология 2007; 3: 4-14).Oganov RG, Glezer MG, Deev AD. Results of the Russian study PARALLEL. The program identifies patients with ineffective therapy with beta-blockers and evaluating the effectiveness of adding the therapy of Trimetazidine MV or isosorbide dinitrate in stable angina. Kardiologija 2007; 3: 4-13. Russian (Оганов Р. Г., Глезер М. Г., Деев Ф. В. Результаты Российского исследования ПАРАЛЛЕЛЬ. Программа по выявлению пациентов с неэффективной терапией бета-адреноблокаторами и сравнительной оценке эффективности добавления к терапии триметазидина МВ или изосорбида динитрата при стабильной стенокардии. Кардиология 2007; 3: 4-14).Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized. double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J 2001; 22: 2267-74.Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized. double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J 2001; 22: 2267-74.Szwed H. Clinical benefits of trimetazidine in patients with recurrent angina. Coron Artrery Dis 2004; 15(Suppl. 1): 17-21.Szwed H. Clinical benefits of trimetazidine in patients with recurrent angina. Coron Artrery Dis 2004; 15(Suppl. 1): 17-21.Chazov EI, Lepakchin VK, Zharova EA, et al. Trimetazine in Angina Combination Therapythe TACT study: trimetazidine versus conventional treatment in patient with stable angina pectoris in randomized, placebo- controlled, mulcenter study. Am J Ther 2005; 12(1): 35-42.Chazov EI, Lepakchin VK, Zharova EA, et al. Trimetazine in Angina Combination Therapythe TACT study: trimetazidine versus conventional treatment in patient with stable angina pectoris in randomized, placebo- controlled, mulcenter study. Am J Ther 2005; 12(1): 35-42.Michaelides A, Spiropoulos K, Dimopoulos K, et al. Antianginal efficacy of the combination of trimetazidine-propranolol compared with isosorbide dinitrate-propranolol in patients with stable angina. Clin Drug Invest 1997; 13: 8-14.Michaelides A, Spiropoulos K, Dimopoulos K, et al. Antianginal efficacy of the combination of trimetazidine-propranolol compared with isosorbide dinitrate-propranolol in patients with stable angina. Clin Drug Invest 1997; 13: 8-14.Vitale C, Spoletini I, Malorni W, et al. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina — the VASCO-аngina study. Int J Cardiol 2013; 168 (2): 1078-81.Vitale C, Spoletini I, Malorni W, et al. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina — the VASCO-аngina study. Int J Cardiol 2013; 168 (2): 1078-81.Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev (2005) CD 003614.Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev (2005) CD 003614.Zhao Y, Peng L, Luo Y, et al. Trimetazidine improves exercise tolerance in patients with ischemic heart disease. A meta-analysis. Herz 2016; 41(6): 514-22.Zhao Y, Peng L, Luo Y, et al. Trimetazidine improves exercise tolerance in patients with ischemic heart disease. A meta-analysis. Herz 2016; 41(6): 514-22.Hu B, Li W, Xu T, et al. Evaluation of trimetazidine in angina pectoris by echocardiography and radionuclide angiography: a meta analysis of randomized, controlled trials. Clin Cardiol 2011; 34: 395-400.Hu B, Li W, Xu T, et al. Evaluation of trimetazidine in angina pectoris by echocardiography and radionuclide angiography: a meta analysis of randomized, controlled trials. Clin Cardiol 2011; 34: 395-400.Orlova EM, Mironova IIu, Matveeva MA, et al. Assessment antianginal and antiischemic effect of trimetazidine and its effects on myocardial perfusion in patients with ischemic heart disease and stable angina. Kardiologiia 2004; 44(9): 23-8. Russian (Орлова Е.М., Миронова И.Ю., Матвеева М.А., и др. Оценка антиангинального и антиишемического эффекта триметазидина и его влияния на миокардиальную перфузию у больных ишемической болезнью сердца и стабильной стенокардией. Кардиология 2004; 44(9): 23-8).Orlova EM, Mironova IIu, Matveeva MA, et al. Assessment antianginal and antiischemic effect of trimetazidine and its effects on myocardial perfusion in patients with ischemic heart disease and stable angina. Kardiologiia 2004; 44(9): 23-8. Russian (Орлова Е.М., Миронова И.Ю., Матвеева М.А., и др. Оценка антиангинального и антиишемического эффекта триметазидина и его влияния на миокардиальную перфузию у больных ишемической болезнью сердца и стабильной стенокардией. Кардиология 2004; 44(9): 23-8).El-Kady T, El-Sabban K, Gabaly M, et al. Effects of trimetazidine on myocardial perfusion and the contractile response on chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drugs 2005: 5: 271-8.El-Kady T, El-Sabban K, Gabaly M, et al. Effects of trimetazidine on myocardial perfusion and the contractile response on chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drugs 2005: 5: 271-8.Lupanov VP. The metabolic myocardial cytoprotector trimetazidine in the treatment of patients with coronary heart disease and related illnesses. Consilium medicum 2014; 16, 5: 37-43. Russian (Лупанов В.П. Метаболический миокардиальный цитопротектор триметазидин в лечении больных ищемической болезнью сердца и сопутствующих заболеваний (обзор). Consilium medicum 2014; 16, 5: 37-43).Lupanov VP. The metabolic myocardial cytoprotector trimetazidine in the treatment of patients with coronary heart disease and related illnesses. Consilium medicum 2014; 16, 5: 37-43. Russian (Лупанов В.П. Метаболический миокардиальный цитопротектор триметазидин в лечении больных ищемической болезнью сердца и сопутствующих заболеваний (обзор). Consilium medicum 2014; 16, 5: 37-43).Нanania G, Haiat R, Olive T, et al. Coronary artery disease observed in general hospitals: ETTIC study. Comparison between trimetazidine and mononitrate isosorbide for patients receiving beta-blockers. Ann Cardiol Angeiol (Paris) 2002; 51: 268-74.Нanania G, Haiat R, Olive T, et al. Coronary artery disease observed in general hospitals: ETTIC study. Comparison between trimetazidine and mononitrate isosorbide for patients receiving beta-blockers. Ann Cardiol Angeiol (Paris) 2002; 51: 268-74.Marzilli M, Affinito S. Meeting the challenge of chronic ischaemic heart disease with trimetazidine. Coron Artery Dis 2005; 16 (Suppl. 1): S23-7.Marzilli M, Affinito S. Meeting the challenge of chronic ischaemic heart disease with trimetazidine. Coron Artery Dis 2005; 16 (Suppl. 1): S23-7.Rodriguez Padial L, Maicas Bellido C, Velazquez Martin M, et al. A prospective study on trimetazidine effectiveness and tolerability in diabetic patients in association to the previous treatment of their coronary disease. DIETRIC study. Rev Clin Esp 2005; 205: 57-62.Rodriguez Padial L, Maicas Bellido C, Velazquez Martin M, et al. A prospective study on trimetazidine effectiveness and tolerability in diabetic patients in association to the previous treatment of their coronary disease. DIETRIC study. Rev Clin Esp 2005; 205: 57-62.Marazzi G, Wajngarten M, Vitale C, et al. Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease. Int J Cardiol 2007; 120: 79-84.Marazzi G, Wajngarten M, Vitale C, et al. Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease. Int J Cardiol 2007; 120: 79-84.Chrusciel P, Rysz J, Banach M. Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insinghts of its role in heart failure and peripheral artery disease. Drugs 2014; 74(9): 871-80.Chrusciel P, Rysz J, Banach M. Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insinghts of its role in heart failure and peripheral artery disease. Drugs 2014; 74(9): 871-80.Lopatin YM, Rosano GM, Fragasso G, et al. Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. Int J Cardiol 2016; 203: 909-15.Lopatin YM, Rosano GM, Fragasso G, et al. Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. Int J Cardiol 2016; 203: 909-15.Fragasso G, Palloshi A, Puccetti P, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006; 48: 992-8.Fragasso G, Palloshi A, Puccetti P, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006; 48: 992-8.Gao D, Ning N, Niu X, et al. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart 2011; 97(4): 278-86.Gao D, Ning N, Niu X, et al. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart 2011; 97(4): 278-86.Danchin N. Clinical benefits of a metabolic approach with trimetazidine in revascularized patients with angina. Am J Cardiol 2006; 98: 8J-13J.Danchin N. Clinical benefits of a metabolic approach with trimetazidine in revascularized patients with angina. Am J Cardiol 2006; 98: 8J-13J.Zhang Y, Ma X-j, Shi D-z. Effect of Trimetazidine in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis. PLOS One 2015, 10(9); e0137775.Zhang Y, Ma X-j, Shi D-z. Effect of Trimetazidine in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis. PLOS One 2015, 10(9); e0137775.Lupanov VP, Maksimenko AV. Protective ischemia in cardiology. Myocardial conditioning forms. Cardiovascular Therapy and Prevention 2011; 10 (1): 96-103. Russian (Лупанов В. П., Максименко А.В. Протективная ишемия в кардиологии. Формы кондиционирования миокарда (обзор). Кардиоваскулярная терапия и профилактика 2011, 10(1): 96-103).Lupanov VP, Maksimenko AV. Protective ischemia in cardiology. Myocardial conditioning forms. Cardiovascular Therapy and Prevention 2011; 10 (1): 96-103. Russian (Лупанов В. П., Максименко А.В. Протективная ишемия в кардиологии. Формы кондиционирования миокарда (обзор). Кардиоваскулярная терапия и профилактика 2011, 10(1): 96-103).D′Ascenzo F, Moretti C, Omede P, et al. Cardiac remote ischaemic preconditioning reduces periprocedural myocardial infarction for patients undergoing percutaneous coronary interventions: a meta-analysis randomised clinical trials. Eurointervention 2014; 9: 1463-71.D′Ascenzo F, Moretti C, Omede P, et al. Cardiac remote ischaemic preconditioning reduces periprocedural myocardial infarction for patients undergoing percutaneous coronary interventions: a meta-analysis randomised clinical trials. Eurointervention 2014; 9: 1463-71.Polonski L, Dec I, Wojnar R, et al. Trimetazidine limits the effects of myocardial ischemia during percutaneous cоrоnary angioplasty. Curr Med Res Opin 2002; 18: 389-96.Polonski L, Dec I, Wojnar R, et al. Trimetazidine limits the effects of myocardial ischemia during percutaneous cоrоnary angioplasty. Curr Med Res Opin 2002; 18: 389-96.Zhang N, Lei JY, Liu Q, et al. The effectiveness of preoperative trimetazidine on myocardial preservation in coronary artery bypass graft patients: a systematic review and metaanalysis. Cardiology 2015; 131: 86-96.Zhang N, Lei JY, Liu Q, et al. The effectiveness of preoperative trimetazidine on myocardial preservation in coronary artery bypass graft patients: a systematic review and metaanalysis. Cardiology 2015; 131: 86-96.Hui D. Trimetazidine treatment of unstable angina pectoris, clinical observation of 50 cases. Clin J Cardiovasc. Rehabil Med 2006; 15(6): 581-3.Hui D. Trimetazidine treatment of unstable angina pectoris, clinical observation of 50 cases. Clin J Cardiovasc. Rehabil Med 2006; 15(6): 581-3.

The authors declare that there are no conflicts of interest present.